Navidea Biopharmaceuticals Aktie [WKN DE: A2PH4J / ISIN: US63937X2027]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Navidea Biopharmaceuticals Inc Registered Shs

03.07.24		Navidea Biopharmaceuticals, Inc. Announces Results of Exploratory Analysis Completed on July 2, 2024 (Businesswire)
21.06.24		Navidea Biopharmaceuticals, Inc. announces special meeting of stockholders to be held July 8, 2024 (Businesswire)
27.01.24		Navidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting Obligations (Businesswire)
01.12.23		Navidea Biopharmaceuticals, CRG Settle All Ongoing Litigation (RTTNews)
01.12.23		Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release (Businesswire)
06.10.23		Navidea Biopharmaceuticals, Inc. Announces NYSE American’s Decision to Suspend Trading In Its Common Stock (Businesswire)
10.08.23		Navidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing Panel (Businesswire)
31.07.23		Navidea Biopharmaceuticals, Inc. Presses Ahead, Embraces Opportunities (Businesswire)
29.07.23		Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination (Businesswire)
27.07.23		Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer (Businesswire)
13.07.23		Navidea Biopharmaceuticals, Inc. Welcomes Dana J Moss, JD to Board of Directors; Amit Bhalla Steps Down (Businesswire)
30.06.23		Navidea Biopharmaceuticals, Inc. Rejects Unsolicited Offer To Acquire Certain Assets (Businesswire)
16.06.23		Navidea Biopharmaceuticals, Inc. Announces Distribution of Series K Preferred Stock to Holders of its Common Stock (Businesswire)
16.06.23		Navidea Biopharmaceuticals, Inc. Receives $7.5 Million Cash from Cardinal Health in Lieu of Contingent Milestone Payment (Businesswire)
07.06.23		Navidea Biopharmaceuticals, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update (Businesswire)
02.06.23		Navidea Biopharmaceuticals, Inc. Receives NYSE American Notice (Businesswire)
01.06.23		Navidea Biopharmaceuticals, Inc. Welcomes Jill Bieker Stefanelli, Ph.D. to Board of Directors; Alexander L. Cappello Steps Down (Businesswire)
23.05.23		Navidea Biopharmaceuticals, Inc. Investors Purchase $1.1 Million in Preferred Shares at Market (Businesswire)
11.05.23		Navidea Biopharmaceuticals, Inc. Promotes Michael Sherman Blue, M.D., FACEP, to Chief Medical Officer (Businesswire)
08.05.23		Navidea Biopharmaceuticals, Inc. Drives Strategy Forward, Shifts Approach for Communications (Businesswire)
27.04.23		Navidea Biopharmaceuticals, Inc. Announces Intent to sell Cardinal Milestone Payment for $8 Million; Secures New $2.75 Million Equity Line of Credit (Businesswire)
13.04.23		Navidea Biopharmaceuticals, Inc. Enters Asset Purchase Agreement with Meilleur Technologies, Inc. for Rights to NAV4694 (Businesswire)
30.03.23		Navidea Biopharmaceuticals, Inc. Hires G2G Ventures as Executive Consultants; Chief Medical Officer Steps Down (Businesswire)
21.03.23		Navidea Biopharmaceuticals Reports Fourth Quarter 2022 Financial Results (Businesswire)
15.03.23		Navidea Biopharmaceuticals to Host Fourth Quarter 2022 Earnings Conference Call and Business Update (Businesswire)
03.01.23		Navidea Biopharmaceuticals Announces the Notice of Allowance for U.S. Patent Application for Key Component of the Company’s Cancer Immunotherapy Pipeline (Businesswire)
01.12.22		Navidea Biopharmaceuticals Files Appeal in CRG Case (Businesswire)
28.11.22		Navidea Biopharmaceuticals Announces 50th Participant Enrolled in the Company’s Phase 3 Trial in Rheumatoid Arthritis (Businesswire)
14.11.22		Navidea Biopharmaceuticals Reports Third Quarter 2022 Financial Results (Businesswire)
07.11.22		Navidea Biopharmaceuticals Announces Details of Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting (Businesswire)
04.11.22		Navidea Biopharmaceuticals to Host Third Quarter 2022 Earnings Conference Call and Business Update (Businesswire)
05.10.22		Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting (Businesswire)
30.09.22		Navidea Biopharmaceuticals Appoints Joshua Wilson to the Board of Directors; Announces Dates Related to its 2022 Annual Meeting of Stockholders (Businesswire)
15.09.22		Navidea Biopharmaceuticals Announces Presentation of Results from its Two Phase 2B Clinical Trials in Rheumatoid Arthritis at Upcoming American College of Rheumatology Annual Meeting (Businesswire)
01.09.22		Navidea Opens New Sites In Phase 3 Trial In Rheumatoid Arthritis; Terminates MOU With Jubilant (RTTNews)
01.09.22		Navidea Biopharma To Assess Court's Judgment In Case Involving Attorney's Fees (RTTNews)
01.09.22		Navidea Biopharmaceuticals Announces Opening of Nine New Sites in its Pivotal Phase 3 Trial in Rheumatoid Arthritis and Termination of Binding Memorandum of Understanding with Jubilant Radiopharma (Businesswire)
01.09.22		Navidea Biopharmaceuticals Announces Oral Ruling in Case Involving Attorney’s Fees (Businesswire)
30.08.22		Navidea Biopharmaceuticals Announces Closing of its Rights Offering and Second Quarter 2022 Earnings Conference Call and Business Update (Businesswire)
25.08.22		Navidea Biopharmaceuticals Announces Subscriptions of Approximately $14.2 Million from its Rights Offering (Businesswire)
18.08.22		Navidea Biopharmaceuticals Announces Extension of Subscription Period to August 24, 2022 and Updated Terms of its Previously Announced Rights Offering (Businesswire)
15.08.22		Navidea Biopharmaceuticals Reports Second Quarter 2022 Financial Results (Businesswire)
04.08.22		Navidea Biopharmaceuticals Announces Commencement of Rights Offering Subscription Period and Updated Terms of its Previously Announced Rights Offering (Businesswire)
01.08.22		Navidea Biopharmaceuticals Announces Publication of Study Examining Use of Tc99m Tilmanocept for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Melanoma and Oral Cancer in Australia (Businesswire)
01.08.22		Navidea Biopharmaceuticals Reminds Investors of Today’s Deadline to be a Shareholder of Record for the Previously Announced Rights Offering (Businesswire)
25.07.22		Navidea Biopharmaceuticals Announces Publication of Study Examining Tc99m Tilmanocept Imaging of Arterial Inflammation in People with HIV (Businesswire)
20.07.22		Navidea Biopharmaceuticals Informs Stockholders of Key Dates and Terms Related to Announced Rights Offering (Businesswire)
05.07.22		Navidea Biopharmaceuticals Announces Additional Bridge Loan Funding (Businesswire)
24.05.22		Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting (Businesswire)
23.05.22		Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the Tumor Myeloid-Directed Therapies Summit Annual Meeting (Businesswire)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

Pierer-Aktie letztlich zweistellig höher: KTM ist insolvent - Antrag auf Sanierung in Eigenverwaltung

voestalpine-Aktie zieht an: Erste Group stuft Aktie von "Accumulate" auf "Buy" hoch

Ripple steigt deutlich: Neues ATH noch in 2024?

Solana Kurs Prognose: 300 US-Dollar noch in diesem Jahr?

Pierer Mobility-Aktie unter Druck: KTM-Pleite - Schockstarre in der Region und bei den Zulieferern - Land OÖ signalisiert Bereitschaft Beschäftigten zu helfen

Rheinmetall-Aktie steigt: Rheinmetall will Munitionswerk in Litauen bauen

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	01.12.2024 12:34
Kaufwert:	EUR
	Hinzufügen Speichern